SureTrader
Home > Boards > Canadian > Biotechs > Nuvo Research Inc. (TSX:NRI)

ST. LOUIS and MISSISSAUGA, ON, Aug. 4 /CNW/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
AC416 Member Profile
Member Level 
Followed By 30
Posts 2,797
Boards Moderated 0
Alias Born 09/29/06
160x600 placeholder
Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement "PR Newswire (Canada)" - 2/8/2016 7:30:00 AM
Nuvo Research® and Horizon Pharma plc Extend Term of Manufacturing Agreement "PR Newswire (US)" - 2/8/2016 7:30:00 AM
Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End "PR Newswire (Canada)" - 1/21/2016 7:30:00 AM
Nuvo Research® Provides Estimated Revenue for the 2015 Fourth Quarter and Year End "PR Newswire (US)" - 1/21/2016 7:30:00 AM
Nuvo Research® Reacquires Pliaglis North American Development and Marketing Rights "PR Newswire (Canada)" - 12/22/2015 7:30:00 AM
Nuvo Research® Reacquires Pliaglis North American Development and Marketing Rights "PR Newswire (US)" - 12/22/2015 7:30:00 AM
Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10™ for the Treatment of Allergic Rhinitis "PR Newswire (Canada)" - 12/21/2015 7:00:00 AM
Nuvo Research® Reports Topline Results of Phase 2 Trial of WF10™ for the Treatment of Allergic Rhinitis "PR Newswire (US)" - 12/21/2015 7:00:00 AM
Nuvo Research® Announces Special Shareholder Meeting to Vote on Reorganization of Nuvo into Two Publicly Traded Companies "PR Newswire (Canada)" - 12/15/2015 7:30:00 AM
Nuvo Research® Announces Special Shareholder Meeting to Vote on Reorganization of Nuvo into Two Publicly Traded Companies "PR Newswire (US)" - 12/15/2015 7:30:00 AM
Nuvo Research® Provides Update on Pennsaid® 2% Phase 3 Clinical Trial "PR Newswire (Canada)" - 12/3/2015 7:30:00 AM
Nuvo Research® Provides Update on Pennsaid® 2% Phase 3 Clinical Trial "PR Newswire (US)" - 12/3/2015 7:30:00 AM
Nuvo Research® Announces Acceleration of Expiry Date of Outstanding Warrants "PR Newswire (Canada)" - 11/30/2015 7:30:00 AM
Nuvo Research® Announces Acceleration of Expiry Date of Outstanding Warrants "PR Newswire (US)" - 11/30/2015 7:30:00 AM
Nuvo Research® Announces TSX Conditional Approval to List Crescita Therapeutics Inc. "PR Newswire (Canada)" - 11/23/2015 7:30:00 AM
Nuvo Research® Announces TSX Conditional Approval to List Crescita Therapeutics Inc. "PR Newswire (US)" - 11/23/2015 7:30:00 AM
Nuvo Research® Announces 2015 Third Quarter Results "PR Newswire (Canada)" - 11/10/2015 5:00:00 PM
Nuvo Research® Announces 2015 Third Quarter Results "PR Newswire (US)" - 11/10/2015 5:00:00 PM
Nuvo Research Announces Successful Pennsaid®2% Phase 3 Trial for Russia "PR Newswire (Canada)" - 11/5/2015 7:15:00 AM
Nuvo Research Announces Successful Pennsaid®2% Phase 3 Trial for Russia "PR Newswire (US)" - 11/5/2015 7:15:00 AM
Nuvo Research® Announces Appointment to its Board of Directors "PR Newswire (Canada)" - 11/3/2015 7:30:00 AM
Nuvo Research® Announces Appointment to its Board of Directors "PR Newswire (US)" - 11/3/2015 7:30:00 AM
Nuvo Research® Announces Intention to Split Into Two Publicly Traded Companies "PR Newswire (Canada)" - 9/15/2015 7:00:00 PM
Nuvo Research® Announces Intention to Split Into Two Publicly Traded Companies "PR Newswire (US)" - 9/15/2015 7:00:00 PM
Nuvo Research® Announces U.S. Patent for Topical Foamed Formulations that Include DMSO "PR Newswire (Canada)" - 8/20/2015 7:30:00 AM
AC416 Member Level  Tuesday, 08/04/09 10:52:08 PM
Re: None
Post # of 82 
ST. LOUIS and MISSISSAUGA, ON, Aug. 4 /CNW/ - Covidien (NYSE:COV - News), a leading global provider of healthcare products, and Nuvo Research Inc. (TSX:NRI - News), a Canadian drug development company, today announced that the U.S. Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee Act (PDUFA) for Pennsaid (diclofenac sodium) topical solution 1.5% w/w of November 4, 2009.

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist